HLA-B*15:02




Test Mnemonic

B1502

CPT Codes

  • 81381 - QTY (1)

Aliases

  • HLA-B*15:02 Genotyping

Performing Laboratory

Allogen Laboratories


Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
5 mLWhole bloodEDTA (Lavender) AmbientSend specimen in original tube.

Alternate Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
7 mLWhole bloodACD A or B (Yellow) Ambient 

Stability

Environmental Condition Description
Ambient1 week
FrozenUnacceptable
Refrigerated1 week

Days Performed

Mon - Fri

Turnaround Time

6 - 8 days

Methodology

Name Description
Polymerase Chain Reaction (PCR) 
Polymerase Chain reaction(PCR)/Sequence Specific Oligo Probes(SSO) 
Sequence based typing, PCR 

Special Info

Identifying individuals of Asian ancestry who are at risk of developing Stevens-Johnson syndrome and toxic epidermal necrolysis when administered carbamazepine, phenytoin, or fosphenytoin therapy

Clinical Info

The allele HLA-B*15:02 is associated with increased risk of developing severe skin reactions (Stevens-Johnson Syndrome and toxic epidermal necrolysis) in individuals of Asian ancestry when treated with Carbamazepine. Treatment with Carbamazepine in subjects positive for HLA-B*15:02 should be avoided. A negative result for HLA-B*15:02 does not rule out the possibility of such reactions. Therapy should be discontinued immediately and permanently should TEN or SJS develop. The FDA recommends that individuals of Asian ancestry be genotyped for the presence of the HLA-B*15:02 allele prior to receiving: -Carbamazepine, a drug used to treat epilepsy, manic/bipolar disorders, and neuropathic pain -Phenytoin and its soluble precursor fosphenytoin, drugs used to control seizures Some studies have also suggested a connection between HLA-B*15:02 positivity and adverse reactions to lamotrigine used for treating epilepsy and bipolar disorder.

Clinical Reference

Positive/Negative